Abbott Laboratories (BVL:ABT)
Peru
· Delayed Price · Currency is PEN · Price in USD 131.60
0.00 (0.00%)
At close: Mar 5, 2026
Abbott Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 44,328 | 41,950 | 40,109 | 43,653 | 43,075 | Upgrade
|
| Revenue Growth (YoY) | 5.67% | 4.59% | -8.12% | 1.34% | 24.46% | Upgrade
|
| Cost of Revenue | 19,210 | 18,644 | 17,919 | 19,083 | 18,080 | Upgrade
|
| Gross Profit | 25,118 | 23,306 | 22,190 | 24,570 | 24,995 | Upgrade
|
| Selling, General & Admin | 11,630 | 11,109 | 10,385 | 10,703 | 11,006 | Upgrade
|
| Research & Development | 2,889 | 2,823 | 2,619 | 2,741 | 2,738 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1,682 | 1,878 | 1,966 | 2,013 | 2,047 | Upgrade
|
| Operating Expenses | 16,201 | 15,810 | 14,970 | 15,457 | 15,791 | Upgrade
|
| Operating Income | 8,917 | 7,496 | 7,220 | 9,113 | 9,204 | Upgrade
|
| Interest Expense | -493 | -559 | -637 | -558 | -533 | Upgrade
|
| Interest & Investment Income | 308 | 344 | 385 | 183 | 43 | Upgrade
|
| Currency Exchange Gain (Loss) | 50 | 27 | -41 | -2 | -1 | Upgrade
|
| Other Non Operating Income (Expenses) | -42 | -23 | -19 | -85 | 7 | Upgrade
|
| EBT Excluding Unusual Items | 8,740 | 7,285 | 6,908 | 8,651 | 8,720 | Upgrade
|
| Merger & Restructuring Charges | -274 | -129 | -144 | -234 | -509 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -143 | - | - | - | Upgrade
|
| Asset Writedown | - | - | -100 | -111 | - | Upgrade
|
| Pretax Income | 8,466 | 7,013 | 6,664 | 8,306 | 8,211 | Upgrade
|
| Income Tax Expense | 1,942 | -6,389 | 941 | 1,373 | 1,140 | Upgrade
|
| Earnings From Continuing Operations | 6,524 | 13,402 | 5,723 | 6,933 | 7,071 | Upgrade
|
| Net Income | 6,524 | 13,402 | 5,723 | 6,933 | 7,071 | Upgrade
|
| Preferred Dividends & Other Adjustments | 24 | 2 | 23 | 28 | 29 | Upgrade
|
| Net Income to Common | 6,500 | 13,400 | 5,700 | 6,905 | 7,042 | Upgrade
|
| Net Income Growth | -51.32% | 134.18% | -17.45% | -1.95% | 57.31% | Upgrade
|
| Shares Outstanding (Basic) | 1,741 | 1,740 | 1,740 | 1,753 | 1,775 | Upgrade
|
| Shares Outstanding (Diluted) | 1,748 | 1,748 | 1,749 | 1,764 | 1,789 | Upgrade
|
| Shares Change (YoY) | - | -0.06% | -0.85% | -1.40% | 0.17% | Upgrade
|
| EPS (Basic) | 3.73 | 7.70 | 3.28 | 3.94 | 3.97 | Upgrade
|
| EPS (Diluted) | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | Upgrade
|
| EPS Growth | -51.31% | 134.36% | -16.62% | -0.76% | 57.38% | Upgrade
|
| Free Cash Flow | 7,395 | 6,351 | 5,059 | 7,804 | 8,648 | Upgrade
|
| Free Cash Flow Per Share | 4.23 | 3.63 | 2.89 | 4.42 | 4.83 | Upgrade
|
| Dividend Per Share | 2.400 | 2.240 | 2.080 | 1.920 | 1.820 | Upgrade
|
| Dividend Growth | 7.14% | 7.69% | 8.33% | 5.50% | 18.95% | Upgrade
|
| Gross Margin | 56.66% | 55.56% | 55.32% | 56.28% | 58.03% | Upgrade
|
| Operating Margin | 20.12% | 17.87% | 18.00% | 20.88% | 21.37% | Upgrade
|
| Profit Margin | 14.66% | 31.94% | 14.21% | 15.82% | 16.35% | Upgrade
|
| Free Cash Flow Margin | 16.68% | 15.14% | 12.61% | 17.88% | 20.08% | Upgrade
|
| EBITDA | 12,033 | 10,714 | 10,463 | 12,380 | 12,742 | Upgrade
|
| EBITDA Margin | 27.15% | 25.54% | 26.09% | 28.36% | 29.58% | Upgrade
|
| D&A For EBITDA | 3,116 | 3,218 | 3,243 | 3,267 | 3,538 | Upgrade
|
| EBIT | 8,917 | 7,496 | 7,220 | 9,113 | 9,204 | Upgrade
|
| EBIT Margin | 20.12% | 17.87% | 18.00% | 20.88% | 21.37% | Upgrade
|
| Effective Tax Rate | 22.94% | - | 14.12% | 16.53% | 13.88% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.